F Rocher
Overview
Explore the profile of F Rocher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martel A, Lagier J, Sarfati E, Malet T, Rocher F, Kauert A, et al.
J Fr Ophtalmol
. 2022 Jun;
45(7):771-783.
PMID: 35718568
Purpose: Filler-induced blindness (FIB) is the most threatening complication following periocular injection. To date, no standard of care has been established. The goal of this study is to report a...
2.
Blaise M, Rocher F, Spittler H, Sanchez A, Lanteri E, Coco L, et al.
J Eur Acad Dermatol Venereol
. 2021 Oct;
36(2):e100-e102.
PMID: 34661938
No abstract available.
3.
Ferrete T, Rocher F, Elmaleh V, Loschi M, Tieulie N, Baillif S, et al.
J Fr Ophtalmol
. 2021 Sep;
44(9):e525-e526.
PMID: 34511309
No abstract available.
4.
Dupre R, Gastaud L, Rocher F, Baillif S, Martel A
J Fr Ophtalmol
. 2021 Aug;
45(1):e5-e6.
PMID: 34384623
No abstract available.
5.
Ferrete T, Rocher F, Elmaleh V, Loschi M, Tieulie N, Baillif S, et al.
J Fr Ophtalmol
. 2021 Apr;
44(5):652-657.
PMID: 33858697
Graft-versus-host disease (GVHD) is a common complication in patients undergoing allogeneic stem cell transplantation for acute myeloblastic leukemia that could be very difficult to treat. Lifitegrast 5% (Xiidra@, Novartis), a...
6.
Lazarescu I, Dubray B, Joulakian M, Blanchard P, Chauvet B, Mahe M, et al.
Cancer Radiother
. 2018 Oct;
22(8):784-789.
PMID: 30348608
Purpose: Cancer caregivers are at high risk of burn-out, with potential severe consequences on professionals' health and on patients' care. We have investigated the prevalence of burn-out and its impact...
7.
Van Obberghen E, Cohen M, Rocher F, Lebrun-Frenay C
Rev Neurol (Paris)
. 2017 Apr;
173(4):222-224.
PMID: 28372806
Natalizumab (NTZ) is an effective treatment for patients with highly active relapsing remitting multiple sclerosis (MS). However, when the therapy must be interrupted, it is important to anticipate the withdrawal...
8.
Viel E, Vanoli A, Melis A, Rocher F, Schipman B, Truong D
Climacteric
. 2016 Apr;
19(3):274-8.
PMID: 27102586
Objectives: This paper aims to highlight the efficiency of auriculotherapy in the treatment of hot flushes, especially in cancer-related menopausal transition. Methods: We used systematically collected data from patients in...
9.
Azria D, Ardiet J, Chauvet B, Denis F, Eschwege F, Hennequin C, et al.
Cancer Radiother
. 2012 Aug;
16(5-6):386-91.
PMID: 22901758
Many clinical studies have showed the key role of radiotherapy in anticancer treatment strategy. Radiations are delivered alone or in combination with systemic therapies. In recent years, the main goal...
10.
Bresch S, Cohen M, Rocher F, Laffon M, Thomas P, Lebrun C
Rev Neurol (Paris)
. 2011 Nov;
168(2):116-20.
PMID: 22100322
Introduction: Natalizumab (NTZ) is a monoclonal antibody used in a single-drug regimen to treat active relapsing remitting multiple sclerosis. Safety data collected during the AFFIRM pivotal study and post marketing...